S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

$1.26
+0.01 (+0.40%)
(As of 10:09 AM ET)
Today's Range
$1.26
$1.29
50-Day Range
$1.06
$1.44
52-Week Range
$0.59
$11.12
Volume
87,147 shs
Average Volume
1.74 million shs
Market Capitalization
$89.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.25

Aclaris Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
1,639.2% Upside
$22.25 Price Target
Short Interest
Healthy
7.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Aclaris Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.98) to ($0.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.96 out of 5 stars

Medical Sector

400th out of 939 stocks

Pharmaceutical Preparations Industry

185th out of 434 stocks

ACRS stock logo

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Stock Price History

ACRS Stock News Headlines

ACRS Apr 2024 1.000 call
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
The Analyst Landscape: 4 Takes On Aclaris Therapeutics
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACRS
Employees
86
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$22.25
High Stock Price Target
$38.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+1,665.9%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-88,480,000.00
Net Margins
-283.15%
Pretax Margin
-284.32%

Debt

Sales & Book Value

Annual Sales
$31.25 million
Book Value
$2.22 per share

Miscellaneous

Free Float
67,024,000
Market Cap
$89.37 million
Optionable
Optionable
Beta
0.21

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Neal S. Walker D.O. (Age 54)
    M.D., Co-Founder, President, Chairman & Interim CEO
    Comp: $955.69k
  • Dr. Joseph Monahan Ph.D. (Age 67)
    Chief Scientific Officer
    Comp: $600.02k
  • Mr. Kevin Balthaser (Age 36)
    Chief Financial Officer
  • Mr. Matthew Rothman J.D.
    General Counsel & Corporate Secretary
  • Dr. Jon Jacobsen Ph.D.
    Senior Vice President of Chemistry
  • Mr. James Loerop (Age 59)
    Chief Business Officer

ACRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACRS, but not buy additional shares or sell existing shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price target for 2024?

7 analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their ACRS share price targets range from $9.00 to $38.00. On average, they predict the company's stock price to reach $22.25 in the next year. This suggests a possible upside of 1,639.2% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2024?

Aclaris Therapeutics' stock was trading at $1.05 on January 1st, 2024. Since then, ACRS stock has increased by 21.8% and is now trading at $1.2793.
View the best growth stocks for 2024 here
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 5,120,000 shares, a decline of 16.1% from the February 29th total of 6,100,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is presently 2.9 days.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. The biotechnology company had revenue of $17.57 million for the quarter, compared to analysts' expectations of $3.96 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 64.56% and a negative net margin of 283.15%.

What ETFs hold Aclaris Therapeutics' stock?
What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.67%), Vanguard Group Inc. (6.66%), Bain Capital Life Sciences Investors LLC (4.94%), Velan Capital Investment Management LP (2.49%), GSA Capital Partners LLP (2.24%) and Monaco Asset Management SAM (1.38%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kamil Ali-Jackson, Kevin Balthaser and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACRS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners